Key Points
- ADARx Pharmaceuticals director Erez Chimovits purchased 61,516 shares at $17.00 each, representing a total investment of approximately $1.05 million.
- Following the transaction, Chimovits directly owned 9,292,025 shares valued at about $158 million, increasing his position by 0.67%. The purchase was disclosed in an SEC filing.
- ADARx is a clinical-stage biopharmaceutical company developing RNA-based treatments for immune-mediated and other serious diseases, including therapies targeting complement and coagulation pathways.
ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX - Get Free Report) Director Erez Chimovits bought 61,516 shares of the business's stock in a transaction that occurred on Monday, September 28th. The stock was purchased at an average price of $17.00 per share, with a total value of $1,045,772.00. Following the completion of the purchase, the director directly owned 9,292,025 shares in the company, valued at $157,964,425. The trade was a 0.67% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
ADARx Pharmaceuticals Price Performance
ADARx Pharmaceuticals stock opened at $19.94 on Thursday. ADARx Pharmaceuticals, Inc. has a 52 week low of $18.50 and a 52 week high of $23.21.
About ADARx Pharmaceuticals
(
Get Free Report)
ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.
ADARx's pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.
Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
